Erythrocyte ENT1-AMPD3 Axis is an Essential Purinergic Hypoxia Sensor and Energy Regulator Combating CKD in a Mouse Model
Hypoxia drives kidney damage and progression of CKD. Although erythrocytes respond rapidly to hypoxia, their role and the specific molecules sensing and responding to hypoxia in CKD remain unclear. In this study, we demonstrated in a mouse model that erythrocyte ENT1-AMPD3 is a master energy regulat...
Saved in:
| Published in: | Journal of the American Society of Nephrology Vol. 34; no. 10; p. 1647 |
|---|---|
| Main Authors: | , , , , , , , , , , , |
| Format: | Journal Article |
| Language: | English |
| Published: |
United States
01.10.2023
|
| Subjects: | |
| ISSN: | 1533-3450, 1533-3450 |
| Online Access: | Get more information |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Abstract | Hypoxia drives kidney damage and progression of CKD. Although erythrocytes respond rapidly to hypoxia, their role and the specific molecules sensing and responding to hypoxia in CKD remain unclear. In this study, we demonstrated in a mouse model that erythrocyte ENT1-AMPD3 is a master energy regulator of the intracellular purinergic hypoxic compensatory response that promotes rapid energy supply from extracellular adenosine, eAMPK-dependent metabolic reprogramming, and O 2 delivery, which combat renal hypoxia and progression of CKD. ENT1-AMPD3-AMPK-BPGM comprise a group of circulating erythroid-specific biomarkers, providing early diagnostic and novel therapeutic targets for CKD.
Hypoxia drives kidney damage and progression of CKD. Although erythrocytes respond rapidly to hypoxia, their role and the specific molecules sensing and responding to hypoxia in CKD remain unclear.
Mice with an erythrocyte-specific deficiency in equilibrative nucleoside transporter 1 ( eEnt1-/- ) and a global deficiency in AMP deaminase 3 ( Ampd3-/- ) were generated to define their function in two independent CKD models, including angiotensin II (Ang II) infusion and unilateral ureteral obstruction (UUO). Unbiased metabolomics, isotopic adenosine flux, and various biochemical and cell culture analyses coupled with genetic studies were performed. Translational studies in patients with CKD and cultured human erythrocytes examined the role of ENT1 and AMPD3 in erythrocyte function and metabolism.
eEnt1-/- mice display severe renal hypoxia, kidney damage, and fibrosis in both CKD models. The loss of eENT1-mediated adenosine uptake reduces intracellular AMP and thus abolishes the activation of AMPK α and bisphosphoglycerate mutase (BPGM). This results in reduced 2,3-bisphosphoglycerate and glutathione, leading to overwhelming oxidative stress in eEnt1-/- mice. Excess reactive oxygen species (ROS) activates AMPD3, resulting in metabolic reprogramming and reduced O 2 delivery, leading to severe renal hypoxia in eEnt1-/- mice. By contrast, genetic ablation of AMPD3 preserves the erythrocyte adenine nucleotide pool, inducing AMPK-BPGM activation, O 2 delivery, and antioxidative stress capacity, which protect against Ang II-induced renal hypoxia, damage, and CKD progression. Translational studies recapitulated the findings in mice.
eENT1-AMPD3, two highly enriched erythrocyte purinergic components that sense hypoxia, promote eAMPK-BPGM-dependent metabolic reprogramming, O 2 delivery, energy supply, and antioxidative stress capacity, which mitigates renal hypoxia and CKD progression. |
|---|---|
| AbstractList | Hypoxia drives kidney damage and progression of CKD. Although erythrocytes respond rapidly to hypoxia, their role and the specific molecules sensing and responding to hypoxia in CKD remain unclear. In this study, we demonstrated in a mouse model that erythrocyte ENT1-AMPD3 is a master energy regulator of the intracellular purinergic hypoxic compensatory response that promotes rapid energy supply from extracellular adenosine, eAMPK-dependent metabolic reprogramming, and O 2 delivery, which combat renal hypoxia and progression of CKD. ENT1-AMPD3-AMPK-BPGM comprise a group of circulating erythroid-specific biomarkers, providing early diagnostic and novel therapeutic targets for CKD.SIGNIFICANCE STATEMENTHypoxia drives kidney damage and progression of CKD. Although erythrocytes respond rapidly to hypoxia, their role and the specific molecules sensing and responding to hypoxia in CKD remain unclear. In this study, we demonstrated in a mouse model that erythrocyte ENT1-AMPD3 is a master energy regulator of the intracellular purinergic hypoxic compensatory response that promotes rapid energy supply from extracellular adenosine, eAMPK-dependent metabolic reprogramming, and O 2 delivery, which combat renal hypoxia and progression of CKD. ENT1-AMPD3-AMPK-BPGM comprise a group of circulating erythroid-specific biomarkers, providing early diagnostic and novel therapeutic targets for CKD.Hypoxia drives kidney damage and progression of CKD. Although erythrocytes respond rapidly to hypoxia, their role and the specific molecules sensing and responding to hypoxia in CKD remain unclear.BACKGROUNDHypoxia drives kidney damage and progression of CKD. Although erythrocytes respond rapidly to hypoxia, their role and the specific molecules sensing and responding to hypoxia in CKD remain unclear.Mice with an erythrocyte-specific deficiency in equilibrative nucleoside transporter 1 ( eEnt1-/- ) and a global deficiency in AMP deaminase 3 ( Ampd3-/- ) were generated to define their function in two independent CKD models, including angiotensin II (Ang II) infusion and unilateral ureteral obstruction (UUO). Unbiased metabolomics, isotopic adenosine flux, and various biochemical and cell culture analyses coupled with genetic studies were performed. Translational studies in patients with CKD and cultured human erythrocytes examined the role of ENT1 and AMPD3 in erythrocyte function and metabolism.METHODSMice with an erythrocyte-specific deficiency in equilibrative nucleoside transporter 1 ( eEnt1-/- ) and a global deficiency in AMP deaminase 3 ( Ampd3-/- ) were generated to define their function in two independent CKD models, including angiotensin II (Ang II) infusion and unilateral ureteral obstruction (UUO). Unbiased metabolomics, isotopic adenosine flux, and various biochemical and cell culture analyses coupled with genetic studies were performed. Translational studies in patients with CKD and cultured human erythrocytes examined the role of ENT1 and AMPD3 in erythrocyte function and metabolism.eEnt1-/- mice display severe renal hypoxia, kidney damage, and fibrosis in both CKD models. The loss of eENT1-mediated adenosine uptake reduces intracellular AMP and thus abolishes the activation of AMPK α and bisphosphoglycerate mutase (BPGM). This results in reduced 2,3-bisphosphoglycerate and glutathione, leading to overwhelming oxidative stress in eEnt1-/- mice. Excess reactive oxygen species (ROS) activates AMPD3, resulting in metabolic reprogramming and reduced O 2 delivery, leading to severe renal hypoxia in eEnt1-/- mice. By contrast, genetic ablation of AMPD3 preserves the erythrocyte adenine nucleotide pool, inducing AMPK-BPGM activation, O 2 delivery, and antioxidative stress capacity, which protect against Ang II-induced renal hypoxia, damage, and CKD progression. Translational studies recapitulated the findings in mice.RESULTSeEnt1-/- mice display severe renal hypoxia, kidney damage, and fibrosis in both CKD models. The loss of eENT1-mediated adenosine uptake reduces intracellular AMP and thus abolishes the activation of AMPK α and bisphosphoglycerate mutase (BPGM). This results in reduced 2,3-bisphosphoglycerate and glutathione, leading to overwhelming oxidative stress in eEnt1-/- mice. Excess reactive oxygen species (ROS) activates AMPD3, resulting in metabolic reprogramming and reduced O 2 delivery, leading to severe renal hypoxia in eEnt1-/- mice. By contrast, genetic ablation of AMPD3 preserves the erythrocyte adenine nucleotide pool, inducing AMPK-BPGM activation, O 2 delivery, and antioxidative stress capacity, which protect against Ang II-induced renal hypoxia, damage, and CKD progression. Translational studies recapitulated the findings in mice.eENT1-AMPD3, two highly enriched erythrocyte purinergic components that sense hypoxia, promote eAMPK-BPGM-dependent metabolic reprogramming, O 2 delivery, energy supply, and antioxidative stress capacity, which mitigates renal hypoxia and CKD progression.CONCLUSIONeENT1-AMPD3, two highly enriched erythrocyte purinergic components that sense hypoxia, promote eAMPK-BPGM-dependent metabolic reprogramming, O 2 delivery, energy supply, and antioxidative stress capacity, which mitigates renal hypoxia and CKD progression. Hypoxia drives kidney damage and progression of CKD. Although erythrocytes respond rapidly to hypoxia, their role and the specific molecules sensing and responding to hypoxia in CKD remain unclear. In this study, we demonstrated in a mouse model that erythrocyte ENT1-AMPD3 is a master energy regulator of the intracellular purinergic hypoxic compensatory response that promotes rapid energy supply from extracellular adenosine, eAMPK-dependent metabolic reprogramming, and O 2 delivery, which combat renal hypoxia and progression of CKD. ENT1-AMPD3-AMPK-BPGM comprise a group of circulating erythroid-specific biomarkers, providing early diagnostic and novel therapeutic targets for CKD. Hypoxia drives kidney damage and progression of CKD. Although erythrocytes respond rapidly to hypoxia, their role and the specific molecules sensing and responding to hypoxia in CKD remain unclear. Mice with an erythrocyte-specific deficiency in equilibrative nucleoside transporter 1 ( eEnt1-/- ) and a global deficiency in AMP deaminase 3 ( Ampd3-/- ) were generated to define their function in two independent CKD models, including angiotensin II (Ang II) infusion and unilateral ureteral obstruction (UUO). Unbiased metabolomics, isotopic adenosine flux, and various biochemical and cell culture analyses coupled with genetic studies were performed. Translational studies in patients with CKD and cultured human erythrocytes examined the role of ENT1 and AMPD3 in erythrocyte function and metabolism. eEnt1-/- mice display severe renal hypoxia, kidney damage, and fibrosis in both CKD models. The loss of eENT1-mediated adenosine uptake reduces intracellular AMP and thus abolishes the activation of AMPK α and bisphosphoglycerate mutase (BPGM). This results in reduced 2,3-bisphosphoglycerate and glutathione, leading to overwhelming oxidative stress in eEnt1-/- mice. Excess reactive oxygen species (ROS) activates AMPD3, resulting in metabolic reprogramming and reduced O 2 delivery, leading to severe renal hypoxia in eEnt1-/- mice. By contrast, genetic ablation of AMPD3 preserves the erythrocyte adenine nucleotide pool, inducing AMPK-BPGM activation, O 2 delivery, and antioxidative stress capacity, which protect against Ang II-induced renal hypoxia, damage, and CKD progression. Translational studies recapitulated the findings in mice. eENT1-AMPD3, two highly enriched erythrocyte purinergic components that sense hypoxia, promote eAMPK-BPGM-dependent metabolic reprogramming, O 2 delivery, energy supply, and antioxidative stress capacity, which mitigates renal hypoxia and CKD progression. |
| Author | Zhang, Xin Lin, Lizhen Kellems, Rodney E D'Alessandro, Angelo Xia, Yang Zhang, Weiru Chen, Changhan Zhang, Yujin Xie, TingTing Wang, Yiyan Brown, Benjamin C Yu, Fang |
| Author_xml | – sequence: 1 givenname: Changhan surname: Chen fullname: Chen, Changhan organization: National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, Hunan, China – sequence: 2 givenname: TingTing orcidid: 0000-0001-6420-5038 surname: Xie fullname: Xie, TingTing organization: Department of General Medicine, Xiangya Hospital, Central South University, Changsha, Hunan, China – sequence: 3 givenname: Yujin surname: Zhang fullname: Zhang, Yujin organization: National Medical Metabolomics International Collaborative Research Center, Xiangya Hospital, Central South University, Changsha, Hunan, China – sequence: 4 givenname: Yiyan orcidid: 0009-0007-6969-2753 surname: Wang fullname: Wang, Yiyan organization: National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, Hunan, China – sequence: 5 givenname: Fang surname: Yu fullname: Yu, Fang organization: Department of Neurology, Xiangya Hospital, Central South University, Changsha, Hunan, China – sequence: 6 givenname: Lizhen orcidid: 0000-0002-7529-4010 surname: Lin fullname: Lin, Lizhen organization: Department of Endocrinology, Xiangya Hospital, Central South University, Changsha, Hunan, China – sequence: 7 givenname: Weiru surname: Zhang fullname: Zhang, Weiru organization: Department of General Medicine, Xiangya Hospital, Central South University, Changsha, Hunan, China – sequence: 8 givenname: Benjamin C orcidid: 0000-0003-4963-8534 surname: Brown fullname: Brown, Benjamin C organization: Department of Endocrinology, Xiangya Hospital, Central South University, Changsha, Hunan, China – sequence: 9 givenname: Xin surname: Zhang fullname: Zhang, Xin organization: National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, Hunan, China – sequence: 10 givenname: Rodney E surname: Kellems fullname: Kellems, Rodney E organization: Department of Biochemistry and Molecular Biology, The University of Texas McGovern Medical School at Houston, Houston, Texas – sequence: 11 givenname: Angelo orcidid: 0000-0002-2258-6490 surname: D'Alessandro fullname: D'Alessandro, Angelo organization: Department of Biochemistry and Molecular Genetics, University of Colorado School of Medicine, Aurora, Colorado – sequence: 12 givenname: Yang orcidid: 0000-0002-8059-6179 surname: Xia fullname: Xia, Yang organization: National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, Hunan, China |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/37725437$$D View this record in MEDLINE/PubMed |
| BookMark | eNpNkN1LwzAQwINM3If-ByJ59KWzSZomfRxbdeI2h5vPJWlvM9Kls2lh_e-NqLDjuM_fHccNUc9WFhC6JeGYxJI8TDarcXguJOEXaEA4YwGLeNg7i_to6NynRzgV4gr1mRCUR0wMUJfWXfNRV3nXAE5XWxJMlusZw5OTcdirsjh1DmxjVInXbW0s1HuT43l3rE5G4Q1YV9UeK3D60-rwG-zbUjW-OK0OWjXG7vH0ZYaNxQovq9aBtwWU1-hyp0oHN39-hN4f0-10Hixen56nk0WQR1zyQDApEgoQJRwgJEpQSWHn812iBdMcEiJ1FGuuI5pQEUvNmFaSa4A8KrSkI3T_u_dYV18tuCY7GJdDWSoL_pqMyjgW3I8Sj979oa0-QJEda3NQdZf9v4t-A2I6bi0 |
| CitedBy_id | crossref_primary_10_1016_j_cmet_2024_06_007 crossref_primary_10_3389_fvets_2024_1511311 crossref_primary_10_1016_j_mcp_2025_102037 crossref_primary_10_1172_JCI192920 crossref_primary_10_1080_0886022X_2024_2336128 crossref_primary_10_3389_fphys_2024_1359357 crossref_primary_10_1097_MOH_0000000000000863 crossref_primary_10_3390_cells13232026 crossref_primary_10_1111_apha_14242 crossref_primary_10_1016_j_transci_2024_104011 |
| ContentType | Journal Article |
| Copyright | Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Society of Nephrology. |
| Copyright_xml | – notice: Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Society of Nephrology. |
| DBID | CGR CUY CVF ECM EIF NPM 7X8 |
| DOI | 10.1681/ASN.0000000000000195 |
| DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
| DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic MEDLINE |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | no_fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1533-3450 |
| ExternalDocumentID | 37725437 |
| Genre | Research Support, Non-U.S. Gov't Journal Article Research Support, N.I.H., Extramural |
| GrantInformation_xml | – fundername: NHLBI NIH HHS grantid: R01 HL146442 – fundername: NHLBI NIH HHS grantid: R01 HL149714 – fundername: NHLBI NIH HHS grantid: R21 HL150032 – fundername: NHLBI NIH HHS grantid: R01 HL148151 |
| GroupedDBID | --- .55 0R~ 18M 29L 2WC 34G 39C 53G 5GY 5RE 5VS 6PF AAQQT AAUIN AAWTL ABBLC ABJNI ABOCM ABXYN ACGFO ACLDA ACZKN ADBBV ADSXY AENEX AFEXH AFFNX AFNMH AHOMT AHQVU ALMA_UNASSIGNED_HOLDINGS BAWUL BTFSW BYPQX CGR CS3 CUY CVF DIK DU5 E3Z EBS ECM EIF EJD ERAAH F5P GX1 HYE HZ~ K-O KQ8 NPM O9- OK1 OVD P0W P2P RHI RIG RPM TEORI TNP TR2 W8F X7M XVB YFH 7X8 |
| ID | FETCH-LOGICAL-c4585-738792ee495ee01a7282efee4f9b73b5e918b46b5b4292768b33ba85beec4db82 |
| IEDL.DBID | 7X8 |
| ISICitedReferencesCount | 16 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=001067155100001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 1533-3450 |
| IngestDate | Sat Nov 01 15:07:12 EDT 2025 Thu Aug 28 04:24:36 EDT 2025 |
| IsDoiOpenAccess | false |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 10 |
| Language | English |
| License | Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Society of Nephrology. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c4585-738792ee495ee01a7282efee4f9b73b5e918b46b5b4292768b33ba85beec4db82 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
| ORCID | 0000-0001-6420-5038 0009-0007-6969-2753 0000-0002-7529-4010 0000-0003-4963-8534 0000-0002-2258-6490 0000-0002-8059-6179 |
| OpenAccessLink | https://doi.org/10.1681/asn.0000000000000195 |
| PMID | 37725437 |
| PQID | 2866759271 |
| PQPubID | 23479 |
| ParticipantIDs | proquest_miscellaneous_2866759271 pubmed_primary_37725437 |
| PublicationCentury | 2000 |
| PublicationDate | 2023-October |
| PublicationDateYYYYMMDD | 2023-10-01 |
| PublicationDate_xml | – month: 10 year: 2023 text: 2023-October |
| PublicationDecade | 2020 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States |
| PublicationTitle | Journal of the American Society of Nephrology |
| PublicationTitleAlternate | J Am Soc Nephrol |
| PublicationYear | 2023 |
| SSID | ssj0015277 |
| Score | 2.5096195 |
| Snippet | Hypoxia drives kidney damage and progression of CKD. Although erythrocytes respond rapidly to hypoxia, their role and the specific molecules sensing and... |
| SourceID | proquest pubmed |
| SourceType | Aggregation Database Index Database |
| StartPage | 1647 |
| SubjectTerms | Adenosine - metabolism AMP Deaminase - genetics AMP Deaminase - metabolism AMP-Activated Protein Kinases - metabolism Animals Erythrocytes - metabolism Humans Hypoxia - metabolism Mice Renal Insufficiency, Chronic - metabolism |
| Title | Erythrocyte ENT1-AMPD3 Axis is an Essential Purinergic Hypoxia Sensor and Energy Regulator Combating CKD in a Mouse Model |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/37725437 https://www.proquest.com/docview/2866759271 |
| Volume | 34 |
| WOSCitedRecordID | wos001067155100001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1ba4MwFA7bOsZedr9fyGCvoSZRE59GWR2DrVLWbvStJBpBGNrVdrT_fidq6dNgMBFBMRLiycn5ci4fQvdKU5gHlBGlwHxzHcWIFo4kJklggWVGOFWG98eriCI5GgX9ZsOtbMIqVzqxUtRJEds98jaTPti2ARP0YfJFLGuU9a42FBqbqMXBlLFSLUZrL4LHKuZFa9IQ7npOkzrnS9ruDKK6dOHqoIH3u5FZLTZP-__t5gHaa8xM3Knl4hBtmPwI7fQaR_oxWobTpWVIiJczg8NoSEmn1-9y3FlkJYZT5TgsbV4SiCfuz-sUwSzGz8tJscgUHgD6LabwWoLDKnsQv9Wk9vAQVIxWNpoaP750cZZjhXvFvDTY8q59nqD3p3D4-EwaFgYSu4AliOBSBMwYQFLGOFQJAGkmhfs00IJrzwRUatfXnrbMV4BeNOdaSU8bE7uJluwUbeVFbs5tGJULDR2hfJq4mmttiyGyhPopSwOp2QW6Ww3qGKTcui5UbqCH4_WwXqCz-s-MJ3U5jjEHgODBly7_0PoK7Vq--Doa7xq1Upjj5gZtx9-zrJzeVuID16jf-wGBWMzp |
| linkProvider | ProQuest |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Erythrocyte+ENT1-AMPD3+Axis+is+an+Essential+Purinergic+Hypoxia+Sensor+and+Energy+Regulator+Combating+CKD+in+a+Mouse+Model&rft.jtitle=Journal+of+the+American+Society+of+Nephrology&rft.au=Chen%2C+Changhan&rft.au=Xie%2C+TingTing&rft.au=Zhang%2C+Yujin&rft.au=Wang%2C+Yiyan&rft.date=2023-10-01&rft.issn=1533-3450&rft.eissn=1533-3450&rft.volume=34&rft.issue=10&rft.spage=1647&rft_id=info:doi/10.1681%2FASN.0000000000000195&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1533-3450&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1533-3450&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1533-3450&client=summon |